Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares ...

Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares ...

Chiasma will eliminate approximately 33% of its workforce—including substantially all its commercial staffers—under a restructuring it said yesterday was intended to focus its resources on ...

Chiasma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Chiasma, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CHMA May 05 ...

--Chiasma, Inc., a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare ...

On its call with analysts, Chiasma said Mycapssa's launch would benefit from the small number endocrinologists actively treating acromegaly in the U.S.—roughly 90% of patients are handled by ...

The stock of Chiasma currently trades just over $4.00 a share and has an approximate market cap of $250 million. The shares came public in 2015 at $16.00 per share. Therefore, the stock is deep in ...

NEWTON, Mass. and JERUSALEM, March 16, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition ...

Chiasma was formed in 2001 and went public in 2015, when it raised more than $106 million. It had priced its stock at $16. As of this writing, the stock is trading at $5.84, giving the company a ...

Shares of ProNAi Therapeutics Inc. and Chiasma Inc. rose quickly following the companies’ initial public offerings Thursday, continuing a solid run of new offerings from venture-backed life ...